News Medical on MSN
Combination therapy offers hope for ending lifelong chronic lymphocytic leukemia treatment
Ianalumab targets the B-cell activating factor receptor (BAFR) and ibrutinib belongs to a class of therapeutics called Bruton ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback